Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Author:

Richardson Paul G.1,Hungria Vânia T. M.2,Yoon Sung-Soo3,Beksac Meral4,Dimopoulos Meletios Athanasios5,Elghandour Ashraf6,Jedrzejczak Wieslaw W.7,Guenther Andreas8,Nakorn Thanyaphong Na9,Siritanaratkul Noppadol10,Schlossman Robert L.1,Hou Jian11,Moreau Philippe12,Lonial Sagar13,Lee Jae Hoon14,Einsele Hermann15,Sopala Monika16,Bengoudifa Bourras-Rezki16,Corrado Claudia16,Binlich Florence17,San-Miguel Jesús F.18

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA;

2. Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil;

3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;

4. Ankara University School of Medicine, Ankara, Turkey;

5. National and Kapodistrian University of Athens, Athens, Greece;

6. Alexandria University, Alexandria, Egypt;

7. Medical University of Warsaw, Warsaw, Poland;

8. Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University Hospital Schleswig-Holstein and University of Kiel, Kiel, Germany;

9. King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand;

10. Siriraj Hospital, Bangkok, Thailand;

11. Chang Zheng Hospital, Shanghai, China;

12. University Hospital of Nantes, Nantes, France;

13. Winship Cancer Institute, Emory University, Atlanta, GA;

14. Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Republic of Korea;

15. Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany;

16. Novartis Pharma AG, Basel, Switzerland;

17. Novartis Pharma SAS, Rueil-Malmaison, France; and

18. Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

Abstract

Key Points Benefit from panobinostat-dexamethasone-bortezomib was greatest in patients who received ≥2 prior regimens including bortezomib and IMiDs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3